Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
03/03/2026 13:03
March 3 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: ARCUTIS BEGINS ENROLLING PHASE 1A/1B STUDY EVALUATING ARQ-234, A CD200R AGONIST, IN HEALTHY VOLUNTEERS AND ADULTS WITH ATOPIC DERMATITIS Source text: ID:nGNX7SCw2N Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Canada Przoryve Cream 0.05% Receives Health Canada Approval For Atopic Dermatitis
Arcutis Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlook
Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4